EMA (EU)
EVENT
EMA workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia
Published: 6/30/2026Detected: 6/29/2026
Summary preview
This EMA workshop convenes multi-stakeholder input to update the EMA “Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia,” with particular…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
hematology
pediatrics
clinical
safety
labeling
#immune thrombocytopenia
#chronic primary immune thrombocytopenia
#clinical development
#clinical trial endpoints
#study design
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026